Simplicity built in. Streamlined for your laboratory.

The Alinity h-series of systems integrates hematology workflow, from high-throughput Complete Blood Count (CBC) analysis to automated slide making and staining. With a bi-directional, internal conveyor and a throughput of 125 CBCs per m2, it delivers high performance in one of the most compact footprints available.

The system is composed of two Alinity hq modules and an Alinity hs module in a hq-hs-hq configuration. The Alinity hq analyzer delivers a CBC with an expanded 6-part White Blood Cell (WBC) differential that includes routine and several advanced parameters using Advanced MAPSS (Multi Angle Polarized Scatter Separation) technology. With the Alinity hs slide maker stainer and the integrated robotic sample management, the Alinity h-series of systems delivers unprecedented uniformity, flexibility, operational productivity and confidence to your customers.

Achieve integration that is built on user-focused design

With an emphasis on addressing needs articulated by you, the Alinity h-series of solutions offer an intuitive and uniform experience, aligned with other Alinity solutions. This commonality in user experience across multiple laboratory disciplines, allows for efficiencies in training, operation, and utilization of staff.

Deliver performance that comes from proven expertise in system and assay design

The Alinity h-series was designed from the ground-up with innovative technology and design elements that will address your need of managing a changing workload with existing resources. Alinity hq and Alinity hs have been designed to help you improve your laboratory’s operational productivity by automating routine processes, allowing your staff to focus on critical tasks.

Not commercially available in all countries, including the USA.

For invitro diagnostics use only.

ADD-00062367
Read more

The CLAM-2000 automates the pretreatment of blood or other biological samples before LC-MS analysis. The background for this development is to minimize variabilities caused by sample pretreatment and manual work. In recent years, there has been considerable progress in the use of mass spectrometers (MS) in the clinical research field due to their highly sensitive detection and high specificity as well as the possibility of multiplexing analysis without the risk of cross reactions inherent to immunoassays. Mass spectrometry enables direct detection of disease-related biological compounds in blood, urine or other biological samples, measurement of trace concentration levels of drugs as well as other applications. However, the bottleneck is still sample preparation which is often tedious, involves risk of errors and increases the risk of contamination of people dealing with sample preparation. By simply placing blood collection tubes in the system, the CLAM-2000 performs all processes through LC-MS analysis automatically. Unlike dispensing systems based on batch processing 96-well plates, the CLAM-2000 is completely automatic from pretreatment to analysis and processes individual sample successively in parallel. Consequently, it results in uniform pretreatment times between samples without slowing processing speed, while improving data reproducibility and accuracy. Pretreatment processes available include dispensing samples, dispensing reagents, stirring, suction filtration, incubation and automatic transfer of sample vials to an SIL-30AC autosampler after pretreatment. CLAM-2000 automates the sample pretreatment for LC-MS analysis. All necessary steps are automatically executed according to an existing method or a method to be developed. It also features excellent management functions providing a dramatically improved workflow with better safety for clinical research and higher reproducibility. It is compatible with the LCMS TQ systems LCMS-8045, LCMS-8050 and LCMS-8060, giving a large choice to adapt to sensitivity needs. The instrument is for research use only and not available in the USA, Canada and China.

Read more

Leptin, the product of the ob (obese) gene, is a single-chain 16 kDa protein consisting of 146 amino acid residues. Leptin is produced mainly in the adipose tissue, and is considered to play an important role in appetite control, fat metabolism and body weight regulation. It targets the central nervous system, particularly the hypothalamus, affecting food intake. The primary effect of leptin appears to be mediated by leptin receptors expressed mainly in the hypothalamus. In humans, leptin levels correlate with body mass index (BMI) and percentage body fat, and are elevated even in obese individuals. Leptin has a dual action; it decreases the appetite and increases energy consumption, causing more fat to be burned. Leptin is secreted in circadian fashion with nocturnal rise in both lean and obese patients. Mutations of the ob gene resulting in leptin deficiency are the cause of obesity in the ob/ob mice. Endogeneous leptin can normalize their body weight. In contrast, high levels of leptin in obese human subjects point to an insensitivity to endogeneous leptin. Other factors in addition to the amount of body fat appear to regulate leptin action: insulin, glucocorticoids, catecholamines and sex hormones. Studies have shown that leptin may be linked to reproductive function.
The BioVendor Leptin ELISA is CE-marked, allowing in vitro diagnostic use in the European Union (research use only in the rest of the world). This sandwich ELISA uses a HRP-labelled antibody and has a total assay time of less than 2.5 hours. The kit measures total leptin in a 96-well assay format. Quality controls are human serum-based and standards are recombinant protein-based. Components of the kit are provided ready to use, concentrated or lyophilized.
Read more

ELITechGroup Molecular Diagnostics announces the CE-IVD marking of the STI ELITe MGB Panel: a multiplex assay for the detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG), three major bacteria involved in sexually transmitted infections. STIs are a global burden with more than 1 million infections acquired every day worldwide.  Accurate and specific detection is important to reduce transmission and complications. In combination with the ELITe InGenius system, the STI ELITe MGB Panel makes it possible to simultaneously detect and differentiate in one single reaction Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium. Patient samples can be directly loaded into the system, which automatically performs all the steps of molecular diagnostics from extraction to result interpretation with minimal hands-on time. The clinical study has demonstrated excellent performance: respectively 96.4%, 100% and 100% diagnostic sensitivity and 100%, 98.4% and 98.4% specificity with C. trachomatis, N. gonorrhoeae and M. genitalium. STI ELITe MGB Panel is the 22nd CE-IVD assay of ELITe InGenius’ menu and the first one intended to diagnose sexually transmitted infections.  Recently identified, M. genitalium is highly prevalent in the general population, and share similar symptoms with C. trachomatis and N. gonorrhoeae, but their specific antibiotic treatments are not fully efficient to cure M. genitalium and generate antibiotics resistance strains. Co-detection of Mycoplasma genitalium, along with Chlamydia trachomatis, Neisseria gonorrhoeae improves the efficiency of STI diagnosis and patient management. ELITe InGenius offers a unique menu with quantitative and qualitative assays for transplant pathogen monitoring, healthcare associated infections, respiratory infections, meningitis, sexually transmitted infections, and the testing of coagulation factors.

Read more